
MATTHEW P. SMELTZER

University of Memphis, School of Public Health
3825 Desoto Avenue, Robison Hall 222, Memphis, TN 38152
E-mail: msmeltzer@memphis.edu
www.memphis.edu/sph/contact/faculty_profiles/smeltzer.php

EDUCATION

PhD	2014	Epidemiology School of Public Health, University of Memphis, Memphis, TN
MStat	2004	Statistics Department of Statistics, University of Florida, Gainesville, FL
BS	2001	Mathematics (cum laude) Harding University, Searcy, AR

TRAINING AND ACCREDITATION

Fellow	2019	Training Institute for Dissemination and Implementation Research in Cancer, National Cancer Institute
PStat	2014-	Accredited Professional Statistician, American Statistical Association

APPOINTMENTS

University Research Professor University of Memphis, School of Public Health	2021-
Associate Professor (tenured), Epidemiology and Biostatistics University of Memphis, School of Public Health	2020-
Assistant Professor (tenure-track), Epidemiology and Biostatistics University of Memphis, School of Public Health	2015-2020
Director of Epidemiology and Biostatistics, Thoracic Oncology Research Group Baptist Cancer Center, Memphis, TN	2016-
Member, Graduate Faculty University of Memphis Graduate School	2015-
Epidemiologist and Biostatistician, Thoracic Oncology Research Group Baptist Cancer Center, Memphis TN	2015-2016
Lead Senior Biostatistician, Department of Biostatistics St. Jude Children's Research Hospital, Memphis, TN	2012-2015
Senior Biostatistician, Department of Biostatistics St. Jude Children's Research Hospital, Memphis, TN	2009-2012
Biostatistical Consultant, Thoracic Oncology Research Group, University of Tennessee Cancer Institute, Memphis, TN	2008-2014

Biostatistician, Department of Biostatistics
St. Jude Children's Research Hospital, Memphis, TN 2006-2009

Statistical Analyst, Department of Biostatistics
St. Jude Children's Research Hospital, Memphis, TN 2004-2006

TEACHING ACTIVITIES

Associate Professor, University of Memphis 2021-

- Epidemiology in Public Health III (Modern Epidemiology) (PUBH 8174) Fall 2020-2021
- Analytic and Research Methods in Public Health I (PUBH 3150) Fall 2020-2021, Spring 2022
- Analytic and Research Methods in Public Health II (PUBH 4151) Spring 2021-2022

Assistant Professor, University of Memphis 2015-2020

- Applied Categorical Data Analysis (PUBH 7311/8311) Spring 2016-2017, Fall 2017-2019
- Applied Survival Analysis (PUBH 7309/8309) Fall 2016, Spring 2018-2020
- Biostatistical Methods I (PUBH 7150/8150) Fall 2015
- Special Problems (PUBH 8400) [Bias and Causation] Spring 2020
- Special Problems (PUBH 8400) [Quantitative Bias Analysis] Fall 2017, Fall 2019
- Masters Thesis (PUBH 7996) Spring 2017

Graduate Teaching Assistant, University of Florida, College of Medicine, 2002

- Evidence Based Medicine (PAS 5013) - Graduate Teaching Assistant

Graduate Teaching Assistant, University of Florida, Department of Statistics, 2001-2003

- Introduction to Statistics (STA 2023)- Graduate Teaching Assistant (4 semesters)
- Mathematical Statistics with Computer Applications (STA 4033) - Graduate Teaching Assistant

HONORS AND AWARDS

2021 University Research Professorship, University of Memphis

2021 Presidential Plenary at IASLC World Conference on Lung Cancer

2017 IASLC Tsuguo Naruke Lectureship Award (Best Surgical Abstract, World Conference on Lung Cancer)

2016 IASLC World Conference on Lung Cancer- Young Investigator Communications Workshop Award

EDITORIALS

1. Roy UB, Baird AM, Ciupek A, Fox J, Manley E Jr, Norris K, Scagliotti GV, Wakelee HA, Mitsudomi T, Clark RC, Arndt R, Hirsch FR, Bunn PA, **Smeltzer MP**. Impact of the Coronavirus Disease 2019 Pandemic on Global Lung Cancer Clinical Trials: Why It Matters to People With Lung Cancer. JTO Clin Res Rep. 2022 Feb;3(2):100269. doi: 10.1016/j.jtocrr.2021.100269. Epub 2021 Dec 23. PMID: 34961851; PMCID: PMC8695593.
2. Oyer RO*, **Smeltzer MP***, Kramar A, Boehmer L, Lathan C. Equity-Driven Approaches to Optimizing Cancer Care Coordination and Reducing Care Delivery Disparities in Underserved Patient Populations in the U.S. JCO Oncol Pract. 2021 May;17(5):215-218. doi: 10.1200/OP.20.00895. Epub 2021 Apr 9. PMID: 33974823 *equal contribution
3. **Smeltzer MP**, Wynes MW, Bunn B, Wakelee HA, Belani CP. Improving Molecular Testing in Lung Cancer: What We Learned From the IASLC Global Survey. IASLC Lung Cancer News, Jan 13, 2021.

4. Osarogiagbon RU, Ray MA, Faris NR, **Smeltzer MP**. Response to: Taichiro Goto: 'Lymph Node Dissection for Non-small-cell Lung Cancer at Whose Discretion?' Comment on our paper titled 'Survival after mediastinal node dissection, systematic sampling or neither for early-stage non-small-cell lung cancer' J Thorac Oncol. 2021, in press.
5. **Smeltzer MP**, Osarogiagbon RU. Out of the darkness, into light: the scientific rigor of lung cancer clinical trials in the age of enlightenment. J Thorac Oncol. 2020, Jul;15(7):1110-1112.
6. Osarogiagbon RU, Ray MA, Faris NR, **Smeltzer MP**. Response to Clinical Thoughts on Mediastinal Node Management in Early-Stage Lung Cancer. J Thorac Oncol. 2020 Nov;15(11):e185-e186. doi: 10.1016/j.jtho.2020.08.028. Epub 2020 Oct 23. PMID: 33148414.
7. Osarogiagbon RU, **Smeltzer MP**, Faris N, Rami-Porta R, Goldstraw P, Asamura H. Comment on the Proposals for the Revision of the N Descriptors in the Forthcoming 8th Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2016 Oct;11(10):1612-4.

PEER-REVIEW PUBLICATIONS

1. **Smeltzer MP**, Ray MA. Statistical Considerations for Outcomes in Clinical Research: A Review of Common Data Types and Methodology. Experimental Biology and Medicine. In press.
2. **Smeltzer MP**, Scagliotti GV, Wakelee HA, Mitsudomi T, Roy UB, Clark RC, Arndt R, Pruett CD, Kelly KL, Ujhazy P, Johnson ML, Eralp Y, Barrios CH, Barlesi F, Hirsch FR, Bunn PA. International Association for the Study of Lung Cancer (IASLC) Study of the Impact of COVID-19 on International Lung Cancer Clinical Trials. Journal Thoracic Oncology, in press.
3. Osarogiagbon RU, Liao W, Faris NR, Meadows-Taylor M, Fehnel C, Lane J, Williams SC, Patel AA, Akinbobola OA, Pacheco A, Epperson A, Luttrell J, McCoy D, McHugh L, Signore R, Bishop AM, Tonkin K, Optican R, Wright J, Robbins T, Ray MA, **Smeltzer MP**. Lung Cancer in Persons Participating in Screening, Lung Nodule Program and Neither: A Prospective Observational Study of the Detecting Early Lung Cancer (DELUGE) in the Mississippi Delta cohort. Journal of Clinical Oncology. In press.
4. Meadows-Taylor M, Faris NR, **Smeltzer MP**, Ray MA, Fehnel C, Akinbobola OA, Ariganjoye F, Patel A, Pacheco A, Mehrotra A, Fox R, Optican R, Tonkin K, Machin J, Wright J, Robbins E, Osarogiagbon R. The Relative Survival Impact of Guideline-Concordant Clinical Staging and Stage-Appropriate Treatment of Potentially Curable Non-Small Cell Lung Cancer. CHEST. In press.
5. Mathias JG, Nolan VG, Klesges LM, Badawy SM, Cooper WO, Hankins JS, **Smeltzer MP**. Hydroxyurea utilization following transitions of care among young adults with sickle cell disease enrolled in Tennessee Medicaid. JAMA Network Open. 2021;4(10):e2128971.
6. **Smeltzer MP**, Howell K, Marsha Treadwell M, Liliana Preiss L, King A, Glassberg J, Paula Tanabe P, Badawy SM, DiMartino L, Gibson R, Kanter J, Klesges LM, Hankins JS, Sickle Cell Disease Implementation Consortium. Barriers to evidence-based care for sickle cell disease in the US: Results from the Sickle Cell Disease Implementation Consortium Provider Needs Assessment. BMJ Open 2021;11:e050880. doi:10.1136/bmjopen-2021-050880
7. **Smeltzer MP**, Hodges TP, Whartenby J, Hankins JS, Davis R, Cooper WO. Three Wishes for Sickle Cell Disease: Results from a multi-stakeholder vision-casting project in Tennessee. Clinical Health Promotion. 2021 Sep. 16;11(2):e21014. <https://doi.org/10.29102/clinhp.21014>
8. Temkin SM, **Smeltzer MP**, Dawkins M, Boehmer LM, Senter L, Black D, Blank SV, Yemelyanova A, Magliocco AM, Finkel M, Moore T, Thaker PH. Improving the Quality of Care for Patients With Advanced Epithelial Ovarian Cancer: Program Components, Implementation Barriers, and Recommendations. Cancer, 17 November 2021, <https://doi.org/10.1002/cncr.34023>

9. Wang W, Freeman M, Hamilton L, Carroll Y, Kang G, Moen J, **Smeltzer MP**, Schreiber J, Heitzer AM, Esteppe J, Aygun B. Developmental screening of three-year-old children with sickle cell disease compared to controls. *Br J Haematol*. 2021 Nov;195(4):621-628. doi: 10.1111/bjh.17780. Epub 2021 Aug 15. PMID: 34396511
10. Chang JG, Regen RB, Peravali R, Harlan SS, **Smeltzer MP**, Kink RJ. Intranasal Fentanyl and Midazolam Use in Children 3 Years of Age and Younger in the Emergency Department. *J Emerg Med*. 2021 Dec;61(6):731-739. doi: 10.1016/j.jemermed.2021.09.006. PMID: 34920841.
11. **Smeltzer MP**, Lee YS, Faris NR, Fehnel C, Akinbobola O, Meadows-Taylor M, Spencer D, Sales E, Okun S, Giampapa C, Anga A, Pacheco A, Ray M, Osarogiagbon RU. Trends in Accuracy and Comprehensiveness of Pathology Reports for Resected Non-small Cell Lung Cancer (NSCLC) in a High Mortality Area of the United States. *J Thorac Oncol*. 2021 Jul 16:S1556-0864(21)02299-1. doi: 10.1016/j.jtho.2021.06.027. Epub ahead of print. PMID: 34280563.
12. Ray M, Faris N, Fehnel C, Derrick A, **Smeltzer M**, Meadows-Taylor M, Arigandoye F, Pacheco A, Optican R, Tonkin K, Wright J, Fox R, Callahan T, Robbins E, Walsh W, Lammers P, Satpute S, Osarogiagbon RU. 2021. Survival Impact of an Enhanced Multidisciplinary Thoracic Oncology Conference in a Regionals Community Healthcare System. *JTO Clin Res Rep* 2021 Jul 3;2(8):100203.
13. **Smeltzer MP**, Faris N, Fehnel C, Akinbobola O, Saulsberry A, Meadows-Taylor M, Pacheco A, Ray M, Osarogiagbon RU. Impact of a Lymph Node Specimen Collection Kit on the Distribution and Survival Implications of the Proposed Revised Lung Cancer Residual Disease Classification: a Propensity-Matched Analysis. *JTO Clin Res Rep*. 2021;2:100161.
14. Elsherif L, Scott LC, Wichlan D, Jones SK, Mathias JG, Shen JH, **Smeltzer MP**, Ataga KI. Hydroxyurea therapy decreases coagulation and endothelial activation in sickle cell disease: a Longitudinal Study. *Br J Haematol*. 2021 Aug;194(3):e71-e73. doi: 10.1111/bjh.17650. Epub 2021 Jul 6. PMID: 34231209.
15. **Smeltzer MP**, Boehmer L, Kramar A, Asfeldt T, Faris N, Amorosi C, Ray M, Nolan V, Oyer R, Lathan C, Osarogiagbon R. An Optimal Care Coordination Model for Medicaid Patients With Lung Cancer: Results From the Beta Model Testing Phase of a Multisite Initiative in the United States. *Oncology Issues*, 36:3, 80-94, DOI: 10.1080/10463356.2021.1901553
16. Ray MA, Fehnel C, Akinbobola O, Faris NR, Meadows-Taylor M, **Smeltzer MP**, Osarogiagbon RU. Comparative Effectiveness of a Lymph Node Collection kit Versus ‘Heightened Awareness’ on Lung Cancer Surgery Quality and Outcomes. *J Thorac Oncol*. 2021 Feb 12:S1556-0864(21)01665-8. doi: 10.1016/j.jtho.2021.01.1618.
17. Thaker P, **Smeltzer MP**, Dawkins M, Senter-Jamieson L, Blank SV, Black D, Finkel M, Yemelyanova A, Boehmer LM, Temkin S. Improving the Quality of Care for Persons with Advanced Epithelial Ovarian Cancer. *Oncology Issues*, 36:2, 36-48, DOI: 10.1080/10463356.2021.1879583
18. Oyer RA, Lathan CS, **Smeltzer MP**, Kramar A, Boehmer L, Asfeldt T. An Optimal Care Coordination Model for Medicaid Patients With Lung Cancer: Finalization of the Model and Implications for Clinical Practice in the U.S. *Oncology Issues*, 36:4, 70-78, DOI: 10.1080/10463356.2021.1930441
19. Osarogiagbon RU, **Smeltzer MP**, Faris NR, Ray MA, Fehnel C, Ojeabulu P, Akinbobola O, Meadows-Taylor M, McHugh LM, Halal AM, Levy P, Sachdev V, Talton R, Wiggins L, Shu X, Shyr Y, Robbins ET, Klesges LM. Outcomes Following Use of a Lymph Node Collection Kit for Lung Cancer Surgery: A Pragmatic, Population-Based, Multi-Institutional, Staggered Implementation Study. *J Thorac Oncol*. 2021 Feb 16:S1556-0864(21)01658-0. doi: 10.1016/j.jtho.2020.12.025.
20. **Smeltzer MP**, Wynes MW, Lantuejoul S, Soo R, Ramalingam SS, VarellaGarcia M, Taylor MM, Richeimer K, Wood K, Howell KE, Dalurzo ML, Felipe E, Hollenbeck G, Kerr K, Kim ES, Mathias C, Pacheco J, Postmus P,

- Powell C, Tsuboi M, Wistuba II, Wakelee HA, Belani CP, Scagliotti GV, Hirsch FR, The International Association for the Study of Lung Cancer (IASLC) Global Survey on Molecular Testing in Lung Cancer, *J Thorac Oncol*. 2020; 15(9):1434–1448.
21. Ray MR, **Smeltzer MP**, Faris N, Osarogiagbon R. Survival After Mediastinal Node Dissection, Systematic Sampling, or Neither for Early Stage NSCLC. *J Thorac Oncol*. 2020; Jun 20;S1556-0864(20)30479-2.
 22. Mathias JG, Nolan V, Meadows-Taylor M, Robinson LA, Howell K, Gurney J, Hankins J, Wang W, Estep J, **Smeltzer MP**. A Meta-analysis of Toxicities Related to Hydroxycarbamide Dosing Strategies. *eJHaem*. 2020; 1: 235– 238. <https://doi.org/10.1002/jha2.7>
 23. Ray MR, Faris N, Derrick A, **Smeltzer MP**, Osarogiagbon R. Rurality, Stage-Stratified Use of Treatment Modalities and Survival of Non-small Cell Lung Cancer. *Chest*. 2020 Aug;158(2):787-796.
 24. Kanter J, Gibson R, Lawrence RH, **Smeltzer MP**, Pugh NL, Glassberg G, Masese RV, King AA, Calhoun C, Hankins JS, Treadwell M. Perceptions of US Adolescents and Adults with Sickle Cell Disease on their Quality of Care. *JAMA Netw Open*. 2020 May 1;3(5):e206016.
 25. Minden-Birkenmaier BA, Meadows MB, Cherukuri K, **Smeltzer MP**, Smith RA, Radic MZ, Bowlin GL. Manuka Honey Modulates the Release Profile of a dHL-60 Neutrophil Model under Anti-Inflammatory Stimulation. *J Tissue Viability*. 2020 May;29(2):91-99. doi: 10.1016/j.jtv.2020.03.005.
 26. Alberts NM, Badawy SM, Hodges J, Estep J, Nwosu C, Khan H, **Smeltzer MP**, Homayuni R, Norell S, Klesges L, Porter JS, Hankins JS. Development of the Mobile App “InCharge Health” to Improve Adherence to Hydroxyurea in Sickle Cell Disease: A User-centered Design Approach. *JMIR Mhealth Uhealth*. 2020 May 8;8(5):e14884.
 27. Osarogiagbon RU, Faris NR, Stevens W, Fehnel C, Houston-Harris C, Ojeabulu P, Akinbobola O, Lee YS, Ray MA, **Smeltzer MP**. Beyond Margin Status: Population-Based Validation of the Proposed IASLC Residual Tumor Classification Re-categorization. *J Thorac Oncol*. 2020 Mar;15(3):371-382.
 28. Williams H, Howell CR, Chemaitilly W, Wilson CL, Karol SE, Nolan VG, **Smeltzer MP**, Green DM, Ehrhardt MJ, Mulrooney DA, Pui CH, Hudson MM, Robison LL, Ness KK. Diabetes among adult survivors of childhood acute lymphoblastic leukemia: A report from the St. Jude Lifetime Cohort Study. *Cancer*. 2020 Feb 15;126(4):870-878. doi: 10.1002/cncr.32596.
 29. Thomas K, Voros B, Meadows-Taylor M, **Smeltzer MP**, Griffin R, Boudreaux JP, Thiagarajan R, Woltering E, Ramirez R. Outcomes of capecitabine and temozolomide (CAPTEM) in advanced neuroendocrine neoplasms (NENs). *Cancers (Basel)*. 2020 Jan 14;12(1). pii: E206. doi: 10.3390/cancers12010206.
 30. Osarogiagbon R, Lee YS, Faris NR, Ray M, Ojeabulu P, **Smeltzer MP**. Invasive Mediastinal Staging for Resected Non-Small Cell Lung Cancer in a Population-Based Cohort. *J Thorac Cardiovasc Surg*. 2019 May 2. pii: S0022-5223(19)30968-7.
 31. Minden-Birkenmaier BA, Meadows MB, Cherukuri K, **Smeltzer MP**, Smith RA, Radic MZ, Bowlin GL. The Effect of Manuka Honey on dHL-60 Cytokine, Chemokine, and Matrix-Degrading Enzyme Release under Inflammatory Conditions. *Med One*. 2019;4(2). pii: e190005. doi: 10.20900/mo.20190005.
 32. Yates AM, Joshi VM, Aygun B, Moen J, Kang G, **Smeltzer MP**, Govindaswamy D, Dowdy J, Cotton A, Ware RE, Hankins JS. Elevated Tricuspid Regurgitation Velocity in Congenital Hemolytic Anemias: Prevalence and Laboratory Correlates. *Pediatr Blood Cancer*. 2019 Jul;66(7):e27717.
 33. Shayeb AM, **Smeltzer MP**, Kaste SC, Brown A, Estep J, Nottage K. Vaso-occlusive crisis as a predictor of symptomatic avascular necrosis in children with sickle cell disease, *Pediatr Blood Cancer*, 2018 Dec;65(12):e27435. doi: 10.1002/pbc.27435.
 34. **Smeltzer MP**, Faris NR, Ray MA, Fehnel C, Houston-Harris C, Ojeabulu P, Akinbobola O, Lee YS, Meadows M, Signore S, Wiggins L, Talton D, Owen E, Deese LE, Eubanks R, Wolf BA, Levy P, Robbins ET,

- Osarogiagbon RU. Survival before and after direct surgical quality feedback in a population-based lung cancer cohort. *Ann Thorac Surg*. 2018 Dec 27. pii: S0003-4975(18)31859-9.
35. Hankins JS, Estep JE, Hodges JR, Villavicencio MA, Robison LL, Weiss MJ, Kang G, Schreiber JE, Porter JS, Kaste SC, Saving KL, Bryant PC, Deyo JE, Nottage KA, King AA, Brandow AM, Lebensburger JD, Adesina O, Chou ST, Zemel BS, **Smeltzer MP**, Wang WC, Gurney JG. Sickle Cell Clinical Research and Intervention Program (SCCRIP): A Lifespan Cohort Study for Sickle Cell Disease Progression from Pediatric into Adulthood. *Pediatr Blood Cancer*. 2018 May 24:e27228. doi: 10.1002/pbc.27228.
 36. **Smeltzer MP**, Rugless F, Jackson B, Foust C, Faris NR, Ray M, Meadows M, Patel A, Roark K, Kedia S, DeBon M, Crossley F, Oliver G, McHugh L, Hastings W, Osborne O, Osborne J, III T, III M, Jones W, Lee HK, Signore RS, Fox R, Li J, Robbins ET, Ward KD, Klesges LM, Osarogiagbon R. Pragmatic Trial of a Multidisciplinary Lung Cancer Care Model in a Community Healthcare Setting: Study Design, Implementation Evaluation, and Baseline Clinical Results. *Transl Lung Cancer Res*. 2018 Feb;7(1):88-102. doi: 10.21037/tlcr.2018.01.02.
 37. Ray MA, Faris NR, **Smeltzer MP**, Fehnel C, Houston-Harris C, Levy P, Wiggins L, Sachdev V, Robbins ET, Spencer D, Osarogiagbon RU. Effectiveness of Implemented Interventions on Pathologic Nodal Staging of Non-Small Cell Lung Cancer, *Ann Thorac Surg*. 2018 Jul;106(1):228-234.
 38. Bi W, Li Y, **Smeltzer MP**, Gao G, Zhao S, Lin X, Kang G. STEPS: An Efficient Prospective Likelihood Approach to Genetic Variant Association analyses of Secondary Traits in Extreme Phenotype Sequencing, *Biostatistics*. 2018 Jul 11. doi: 10.1093/biostatistics/kxy030.
 39. **Smeltzer MP**, Faris NR, Ray MA, Osarogiagbon RU. Association of pathologic nodal staging quality with survival among patients with non-small cell lung cancer after resection with curative intent. *JAMA Oncol*. 2018; 4(1):1-8. Published September 28, 2017. doi:10.1001/jamaoncol.2017.2993
 40. Fetz AE, Neeli I, Buddington KK, Read RW, **Smeltzer MP**, Radic MZ, Bowlin GL. Localized Delivery of Cl-Amidine From Electrospun Polydioxanone Templates to Regulate Acute Neutrophil NETosis: A Preliminary Evaluation of the PAD4 Inhibitor for Tissue Engineering. *Front. Pharmacol*. 2018; 9:289. doi: 10.3389/fphar.2018.00289
 41. Nolan VG, Anderson SM, **Smeltzer MP**, Porter JS, Carroll YM, Brooks IM, Elmagboul N, Gurney JG, Hankins JS. Pediatric to Adult Care Co-location Transitional Model for Youth with Sickle Cell Disease. *Am J Hematol*. 2018 Jan;93(1):E30-E32.
 42. Estep JH, **Smeltzer MP**, Kang G, Li C, Wang WC, Abrams C, Aygun B, Ware RE, Nottage K, Hankins JS. A Clinically Meaningful Fetal Hemoglobin Threshold for Children with Sickle Cell Anemia During Hydroxyurea Therapy. *Am J Hematol*. 2017 Dec;92(12):1333-1339.
 43. Estep JH, **Smeltzer MP**, Kang G, Howard SC, Reiss UM. Safe Use of Low Molecular Weight Heparin in Pediatric Acute Lymphoblastic Leukemia and Lymphoma Around Lumbar Punctures. *J Pediatr Hematol Oncol*. 2017 Nov;39(8):596-601.
 44. Lin CC, **Smeltzer MP**, Jemal A, Osarogiagbon R. Risk-Adjusted Margin Positivity Rate as a Surgical Quality Metric for Non-Small-Cell Lung Cancer. *Ann Thorac Surg* 2017;104:1161–70.
 45. **Smeltzer MP**, Lin CC, Kong FM, Jemal A, and Osarogiagbon RU. Survival Impact of Post-Operative Therapy Modalities According to Margin Status in Non-Small Cell Lung Cancer Patients in the United States. *J Thorac Cardiovasc Surg*. 2017 Apr 4. pii: S0022-5223(17)30604-9.
 46. Osarogiagbon R, Ray M, Faris N, **Smeltzer MP**, Fehnel C, Houston-Harris C, Signore R, McHugh L, Levy P, Wiggins L, Sachdev V, Robbins E. Prognostic Value of National Comprehensive Cancer Network Lung Cancer Resection Quality Parameters. *Ann Thorac Surg*. 2017 May;103(5):1557-1565.

47. Faris N, **Smeltzer MP**, Lu F, Fehnel C, Chakraborty N, Houston-Harris C, Robbins E, Signore R, McHugh L, Wolf B, Wiggins L, Levy P, Sachdev V, Osarogiagbon R. Evolution in the Surgical Care of Non-Small Cell Lung Cancer (NSCLC) Patients in the Mid-South Quality of Surgical Resection (MS-QSR) Cohort. *Sem. Card. Vasc. Surg.*, Spring 2017, Volume 29, Issue 1, Pages 91–101.
48. Loeffler RB, McCarville MB, Wilson A, **Smeltzer M**, Krafft AJ, Song R, Hankins J, Hillenbrand CM. Can Multi-slice or Navigator-gated R2*-MRI Replace Single-slice Breath-hold Acquisition for Hepatic Iron Quantification? *Pediatr Radiol.* 2017 Jan;47(1):46-54.
49. Sachdev JC, Snider JN, Allen JW, Schwartzberg LS, Young RR, Javed AY, **Smeltzer MP**, Yunus F, Verrier CS, Jahanzeb M. Neoadjuvant Weekly nab-Paclitaxel Plus Carboplatin Followed by Doxorubicin Plus Cyclophosphamide With Bevacizumab Added Concurrently to Chemotherapy for Palpable and Operable Triple-Negative Invasive Breast Cancer. *Journal of Cancer and Allied Specialties.* 2016; 2(1).
50. Nottage K, Ware RE, Aygun B, **Smeltzer MP**, Kang G, Moen J, Wang W, Hankins J, Helton K,. Hydroxycarbamide Treatment and Brain MRI/MRA Findings in Children with Sick Cell Anaemia. *Br J Haematol.* 2016 Oct;175(2):331-338.
51. Li Q, Zhan P, Dongmei Y, Lv Y, Krupnick AS, Passaro A, Brunelli A, **Smeltzer MP**, Osarogiagbon RU, Song Y. Prognostic value of lymph node ratio in patients with pathological N1 non-small cell lung cancer: a systematic review with meta-analysis. *Transl Lung Cancer Res.* 2016 Jun;5(3):258-64.
52. **Smeltzer MP**, Faris N, Yu X, Spencer D, Berry A, Sales E, Finch-Cruz C, Osarogiagbon RO. The Survival Impact of Missed Lymph Node Metastasis in Surgically Resected Non-Small Cell Lung Cancer. *Ann Thorac Surg.* 2016 Aug;102(2):448-53.
53. Nottage KA, Hankins JS, James D, Richardson J, Christensen R, Kang G, **Smeltzer MP**, Cancio M, Wang WC, Anghelescu D. Addressing Challenges of Clinical Trials in Acute Pain: The Pain Management of Vaso-occlusive Crisis in Sick Cell Disease Study. *Clin Trials.* 2016 Aug;13(4):409-16.
54. **Smeltzer MP**, Nolan VG, Yu X, Nottage KA, Davis B, Yang Y, Wang WC, Gurney JG, Hankins JS. The Birth Prevalence of Sick Cell Trait and Sick Cell Disease in Shelby County, TN. *Pediatr Blood Cancer.* 2016 Jun;63(6):1054-9.
55. Osarogiagbon RU, Lin CC, **Smeltzer MP**, Jemal A. Prevalence, prognostic implications and survival modulators of incompletely resected non-small-cell lung cancer in the US National Cancer Data Base. *Journal of Thoracic Oncology, J Thorac Oncol.* 2016 Jan;11(1):e5-e16. PMID: 26762752
56. Pestina T, Hargrove PW, Zhao HF, **Smeltzer MP**, Weiss MJ, Wilber A, Persons DA. Amelioration of murine sickle cell disease by nonablative conditioning and γ -globin gene-corrected bone marrow cells. *Mol Ther Methods Clin Dev.* 2015;2:15045.
57. Hankins JS, McCarville MB, Rankine-Mullings A, Reid ME, Lobo C, Moura P, Ali S, Soares D, Aldred K, Jay DW, Aygun B, Bennett J, Kang G, Goldsmith JC, **Smeltzer MP**, Boyett JM, Ware RE. Prevention of Conversion to Abnormal TCD with Hydroxyurea in Sickle Cell Anemia: A Phase II International Randomized Clinical Trial. *American Journal of Hematology,* 2015 90(12): 1099–1105.
58. **Smeltzer MP**, Nolan VG, Yu X, Nottage KA, Wang WC, Hankins JS, Gurney JG. The Effects of Distance from an Urban Sickle Cell Center on Routine Healthcare Management and Rates of Hospitalization. *Hemoglobin,* 2015 Sep 15:1-6. [Epub ahead of print] PMID: 26372097
59. Yu X, Klesges L, **Smeltzer MP**, Osarogiagbon R. Measuring improvement in populations: implementing and evaluating successful change in lung cancer care. *Trans. Lung Cancer Research,* 2015; 4(4): 373-384.

60. Cancio MI, Helton KJ, Schreiber JE, **Smeltzer MP**, Kang G, Wang WC. Silent cerebral infarcts in very young children with sickle cell anaemia are associated with a higher risk of stroke. *British Journal of Haematology*, 2015 Oct;171(1):120-9.
61. Porter JS, Matthews CS, Carroll YM, Anderson SM, **Smeltzer MP**, Hankins JS. Genetic education and sickle cell disease: Feasibility and efficacy of a program tailored to adolescents. *Journal of Pediatric Hematology and Oncology*; 36 (7), 572-577, 2014
62. Hankins JS, Aygun B, Nottage K, Thornburg C, **Smeltzer MP**, Ware RE, Wang WC. From Infancy to Adolescence: Fifteen Years of Continuous Treatment with Hydroxyurea in Sickle Cell Anemia. *Medicine*, 93(28):e215, 2014.
63. Estep JH, Winter B, Johnson M, **Smeltzer MP**, Howard SC, Hankins JS. Improved hydroxyurea effect with the use of text messaging in children with sickle cell anemia. *Pediatric Blood and Cancer*; 61(11):2031-36, 2014.
64. Nottage KA, Ware RE, Winter B, **Smeltzer M**, Wang WC, Hankins JS, Dertinger SD, Shulkin B, and Aygun B. Predictors of splenic function preservation in children with sickle cell anemia treated with hydroxyurea. *Eur J Haematol*. 2014; 93(5):377-83
65. Bettini M, Jennifer L. Blanchfield JL, Castellaw A, Zhang Q, Nakayama M, **Smeltzer MP**, Zhang H, Hogquist KA, Evavold BD, Vignali DA. TCR affinity and tolerance mechanisms converge to shape T cell diabetogenic potential. *J Immunol*. 2014 Jul 15;193(2):571-9.
66. Helton, KG; Reddick, W; Paydar, A; Zandieh, A, Dave, R; **Smeltzer, MP**; Wu, S; Hankins, J; Aygun, B; Ogg, R Comparing segmented ASL perfusion of vascular territories using manual vs. semi-automated techniques in children with sickle cell anemia. *Journal of Magnetic Resonance Imaging*. 2015, 41:439–446.
67. Hankins, J; **Smeltzer, M**; Wu, S; Aygun, B; Clarke, D. Assessment of Sleep-Related Disorders in Children with Sickle Cell Disease. *Hemoglobin* 2014;38(4):244-51.
68. Osarogiagbon RU; Wang, CG; Miller LE; Adair CA; **Smeltzer M**; Yu X; Berry A. Size and histologic characteristics of lymph node material retrieved from remnant tissue after routine pathologic examination of lung cancer resection specimens. *Ann. of Diagn. Pathol*. 2014 Jun;18(3):136-9.
69. Nottage KA, Hankins JS, **Smeltzer M**, Mzayek F, Wang WC, Aygun B, Gurney JG. Hydroxyurea use and hospitalization trends in a comprehensive pediatric sickle cell program. *PLoS one*. 2013;8(8):e72077.
70. Sheehan VA, Hansbury EN, **Smeltzer MP**, Fortner G, McCarville MB, Aygun B. Transcranial Doppler velocity and brain MRI/MRA changes in children with sickle cell anemia on chronic transfusions to prevent primary stroke. *Pediatric blood & cancer*. Sep 2013;60(9):1499-1502.
71. Osarogiagbon RU, Ramirez RA, Wang CG, Miller LE, **Smeltzer M**, Sareen S, Javed AY, Robbins SG, Khandekar A, Wolf BA, Gibson J, Spencer D, Robbins ET. Dual intervention to improve pathologic staging of resectable lung cancer. *The Annals of thoracic surgery*. Dec 2013;96(6):1975-1981.
72. Despotovic JM, McGann PT, **Smeltzer M**, Aygun B, Ware RE. RHD zygosity predicts degree of platelet response to anti-D immune globulin treatment in children with immune thrombocytopenia. *Pediatric blood & cancer*. Sep 2013;60(9):E106-108.
73. Guy CS, Vignali KM, Temirov J, Bettini ML, Overacre AE, **Smeltzer M**, Zhang H, Huppa JB, Tsai YH, Lobry C, Xie J, Dempsey PJ, Crawford HC, Aifantis I, Davis MM, Vignali DA. Distinct TCR signaling pathways drive proliferation and cytokine production in T cells. *Nature immunology*. Mar 2013;14(3):262-270.
74. Estep JH, **Smeltzer MP**, Wang WC, Hoehn ME, Hankins JS, Aygun B. Protection from sickle cell retinopathy is associated with elevated HbF levels and hydroxycarbamide use in children. *British journal of haematology*. May 2013;161(3):402-405.

75. Cook CM, **Smeltzer MP**, Mortier NA, Kirk SE, Despotovic JM, Ware RE, Hankins JS. The clinical and laboratory spectrum of Hb C [beta6(A3)Glu-->Lys, GAG>AAG] disease. *Hemoglobin*. 2013;37(1):16-25.
76. Yates AM, Dedeken L, **Smeltzer MP**, Lebensburger JD, Wang WC, Robitaille N. Hydroxyurea treatment of children with hemoglobin SC disease. *Pediatric blood & cancer*. Feb 2013;60(2):323-325.
77. Aygun B, Mortier NA, **Smeltzer MP**, Shulkin BL, Hankins JS, Ware RE. Hydroxyurea treatment decreases glomerular hyperfiltration in children with sickle cell anemia. *American journal of hematology*. Feb 2013;88(2):116-119.
78. Finch P, Stocks RM, **Smeltzer MP**, Kimble A, Schoumacher R, Hankins JS. Effects of adenotonsillectomy on polysomnographic parameters in children with sickle cell disease. *Pediatric blood & cancer*. Jul 2013;60(7):E26-28.
79. Nottage K, Gurney JG, **Smeltzer M**, Castellanos M, Hudson MM, Hankins JS. Trends in transfusion burden among long-term survivors of childhood hematological malignancies. *Leukemia & lymphoma*. Aug 2013;54(8):1719-1723.
80. Anghelescu DL, Burgoyne LL, Faughnan LG, Hankins GM, **Smeltzer MP**, Pui CH. Prospective randomized crossover evaluation of three anesthetic regimens for painful procedures in children with cancer. *The Journal of pediatrics*. Jan 2013;162(1):137-141.
81. Hankins JS, Osarogiagbon R, Adams-Graves P, McHugh L, Steele V, **Smeltzer MP**, Anderson SM. A transition pilot program for adolescents with sickle cell disease. *Journal of pediatric health care : official publication of National Association of Pediatric Nurse Associates & Practitioners*. Nov-Dec 2012;26(6):e45-49.
82. Cejda KR, **Smeltzer MP**, Hansbury EN, McCarville ME, Helton KJ, Hankins JS. The impact of preparation and support procedures for children with sickle cell disease undergoing MRI. *Pediatric radiology*. Oct 2012;42(10):1223-1228.
83. Williams-Hooker R, Olivi S, **Smeltzer MP**, Wang W. Health-Related Quality of Life is Associated with Hemoglobin Level in Children with Sickle Cell Anemia. *J Blood Disorders Transf*. 2012;3(4).
84. McCullers JA, Williams BF, Wu S, **Smeltzer MP**, Williams BG, Hayden RT, Howard SC, Pui CH, Hughes WT. Healthcare-Associated Infections at a Children's Cancer Hospital, 1983-2008. *Journal of the Pediatric Infectious Diseases Society*. Mar 2012;1(1):26-34.
85. Woo SR, Turnis ME, Goldberg MV, Bankoti J, Selby M, Nirschl CJ, Bettini ML, Gravano DM, Vogel P, Liu CL, Tansombatvisit S, Grosso JF, Netto G, **Smeltzer MP**, Chaux A, Utz PJ, Workman CJ, Pardoll DM, Korman AJ, Drake CG, Vignali DA. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape. *Cancer research*. Feb 15 2012;72(4):917-927.
86. Estep JH, **Smeltzer M**, Reiss UM. The impact of quality and duration of enoxaparin therapy on recurrent venous thrombosis in children. *Pediatric blood & cancer*. Jul 15 2012;59(1):105-109.
87. Ware RE, Despotovic JM, Mortier NA, Flanagan JM, He J, **Smeltzer MP**, Kimble AC, Aygun B, Wu S, Howard T, Sparreboom A. Pharmacokinetics, pharmacodynamics, and pharmacogenetics of hydroxyurea treatment for children with sickle cell anemia. *Blood*. Nov 3 2011;118(18):4985-4991.
88. Walker AL, Steward S, Howard TA, Mortier N, **Smeltzer M**, Wang YD, Ware RE. Epigenetic and molecular profiles of erythroid cells after hydroxyurea treatment in sickle cell anemia. *Blood*. Nov 17 2011;118(20):5664-5670.
89. Zou P, Helton KJ, **Smeltzer M**, Li CS, Conklin HM, Gajjar A, Wang WC, Ware RE, Ogg RJ. Hemodynamic responses to visual stimulation in children with sickle cell anemia. *Brain imaging and behavior*. Dec 2011;5(4):295-306.

90. Aygun B, Mortier NA, **Smeltzer MP**, Hankins JS, Ware RE. Glomerular hyperfiltration and albuminuria in children with sickle cell anemia. *Pediatric nephrology*. Aug 2011;26(8):1285-1290.
91. Aygun B, Parker J, Freeman MB, Stephens AL, **Smeltzer MP**, Wu S, Hankins JS, Wang WC. Neurocognitive screening with the Brigance preschool screen-II in 3-year-old children with sickle cell disease. *Pediatric blood & cancer*. Apr 2011;56(4):620-624.
92. Fowler KT, Williams R, Mitchell CO, Levy MC, Pope LF, **Smeltzer MP**, Wang WC. Dietary water and sodium intake of children and adolescents with sickle cell anemia. *Journal of pediatric hematology/oncology*. Jul 2010;32(5):350-353.
93. McCarville MB, Hillenbrand CM, Loeffler RB, **Smeltzer MP**, Song R, Li CS, Hankins JS. Comparison of whole liver and small region-of-interest measurements of MRI liver R2* in children with iron overload. *Pediatric radiology*. Aug 2010;40(8):1360-1367.
94. Hankins JS, **Smeltzer MP**, McCarville MB, Aygun B, Hillenbrand CM, Ware RE, Onciu M. Patterns of liver iron accumulation in patients with sickle cell disease and thalassemia with iron overload. *European journal of haematology*. Jul 2010;85(1):51-57.
95. Hankins JS, McCarville MB, Hillenbrand CM, Loeffler RB, Ware RE, Song R, **Smeltzer MP**, Joshi V. Ventricular diastolic dysfunction in sickle cell anemia is common but not associated with myocardial iron deposition. *Pediatric blood & cancer*. Sep 2010;55(3):495-500.
96. Flanagan JM, Howard TA, Mortier N, Avlasevich SL, **Smeltzer MP**, Wu S, Dertinger SD, Ware RE. Assessment of genotoxicity associated with hydroxyurea therapy in children with sickle cell anemia. *Mutation research*. Apr 30 2010;698(1-2):38-42.
97. Hankins JS, McCarville MB, Loeffler RB, **Smeltzer MP**, Onciu M, Hoffer FA, Li CS, Wang WC, Ware RE, Hillenbrand CM. R2* magnetic resonance imaging of the liver in patients with iron overload. *Blood*. May 14 2009;113(20):4853-4855.
98. McCarville MB, Monu N, **Smeltzer MP**, Li CS, Laningham FH, Morris EB, Shulkin BL. PET-CT of the normal spinal cord in children. *Academic radiology*. Jul 2009;16(7):881-885.
99. Karplus G, McCarville MB, **Smeltzer MP**, Spyridis G, Rao BN, Davidoff A, Li CS, Shochat S. Should contralateral exploratory thoracotomy be advocated for children with osteosarcoma and early unilateral pulmonary metastases? *Journal of pediatric surgery*. Apr 2009;44(4):665-671.
100. Helton KJ, Paydar A, Glass J, Weirich EM, Hankins J, Li CS, **Smeltzer MP**, Wang WC, Ware RE, Ogg RJ. Arterial spin-labeled perfusion combined with segmentation techniques to evaluate cerebral blood flow in white and gray matter of children with sickle cell anemia. *Pediatric blood & cancer*. Jan 2009;52(1):85-91.
101. Mahindroo N, Connelly MC, Punchihewa C, Kimura H, **Smeltzer MP**, Wu S, Fujii N. Structure-activity relationships and cancer-cell selective toxicity of novel inhibitors of glioma-associated oncogene homologue 1 (Gli1) mediated transcription. *Journal of medicinal chemistry*. Jul 23 2009;52(14):4277-4287.
102. McCarville MB, Goodin GS, Fortner G, Li CS, **Smeltzer MP**, Adams R, Wang W. Evaluation of a comprehensive transcranial doppler screening program for children with sickle cell anemia. *Pediatric blood & cancer*. Apr 2008;50(4):818-821.
103. Burton AR, Vincent E, Arnold PY, Lennon GP, **Smeltzer M**, Li CS, Haskins K, Hutton J, Tisch RM, Sercarz EE, Santamaria P, Workman CJ, Vignali DA. On the pathogenicity of autoantigen-specific T-cell receptors. *Diabetes*. May 2008;57(5):1321-1330.

104. Hankins JS, Fortner GL, McCarville MB, **Smeltzer MP**, Wang WC, Li CS, Ware RE. The natural history of conditional transcranial Doppler flow velocities in children with sickle cell anaemia. *British journal of haematology*. Jul 2008;142(1):94-99.
105. McCarville MB, Whittle SB, Goodin GS, Li CS, **Smeltzer MP**, Hale GA, Kaufman RA. Clinical and CT features of benign pneumatosis intestinalis in pediatric hematopoietic stem cell transplant and oncology patients. *Pediatric radiology*. Oct 2008;38(10):1074-1083.
106. Morris EB, Shelso J, **Smeltzer MP**, Thomas NA, Karimova EJ, Li CS, Merchant T, Gajjar A, Kaste SC. The use of bone age for bone mineral density interpretation in a cohort of pediatric brain tumor patients. *Pediatric radiology*. Dec 2008;38(12):1285-1292.
107. Razzouk BI, Rose SR, Hongeng S, Wallace D, **Smeltzer MP**, Zacher M, Pui CH, Hudson MM. Obesity in survivors of childhood acute lymphoblastic leukemia and lymphoma. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology*. Apr 1 2007;25(10):1183-1189.
108. Burgoyne LL, **Smeltzer MP**, Pereiras LA, Norris AL, De Armendi AJ. How well do pediatric anesthesiologists agree when assigning ASA physical status classifications to their patients? *Paediatric anaesthesia*. Oct 2007;17(10):956-962.

PEER-REVIEW CONSORTIUM PUBLICATIONS

109. DiMartino LD, Baumann AA, Hsu LL, Kanter J, Gordeuk VR, Glassberg J, Treadwell MJ, Melvin CL, Telfair J, Klesges LM, King A, Wun T, Shah N, Gibson RW, Hankins JS; **Sickle Cell Disease Implementation Consortium**. The sickle cell disease implementation consortium: Translating evidence-based guidelines into practice for sickle cell disease. *Am J Hematol*. 2018 Dec;93(12):E391-E395. doi: 10.1002/ajh.25282.
110. Baumann AA, Belle SH, James A, King AA; **Sickle Cell Disease Implementation Consortium**. Specifying sickle cell disease interventions: a study protocol of the Sickle Cell Disease Implementation Consortium (SCDIC). *BMC Health Serv Res*. 2018 Jun 27;18(1):500. doi: 10.1186/s12913-018-3297-1.
111. Knisely MR, Pugh N, Kroner B, Masese R, Gordeuk V, King AA, Smith SM, Gurney JG, Adams R, Wun T, Snyder A, Glassberg J, Shah N, Treadwell M; **Sickle Cell Disease Implementation Consortium**. Patient-reported outcomes in sickle cell disease and association with clinical and psychosocial factors: Report from the sickle cell disease implementation consortium. *Am J Hematol*. 2020 Sep;95(9):1066-1074. doi: 10.1002/ajh.25880. Epub 2020 Jun 29. PMID: 32449965.
112. Glassberg JA, Linton EA, Burson K, Hendershot T, Telfair J, Kanter J, Gordeuk VR, King AA, Melvin CL, Shah N, Hankins JS, Epié AY, Richardson LD; **Sickle Cell Disease Implementation Consortium**. Publication of data collection forms from NHLBI funded sickle cell disease implementation consortium (SCDIC) registry. *Orphanet J Rare Dis*. 2020 Jul 7;15(1):178. doi: 10.1186/s13023-020-01457-x. PMID: 32635939; PMCID: PMC7341606.
113. Masese RV, DeMartino T, Bonnabeau E, Burns EN, Preiss L, Varughese T, Nocek JM, Lasley P, Chen Y, Davila C, Nwosu C, Scott S, Bowman L, Gordon L, Clesca C, Peters-Lawrence M, Melvin C, Shah N, Tanabe P; **SCD Implementation Consortium**. Effective Recruitment Strategies for a Sickle Cell Patient Registry Across Sites from the Sickle Cell Disease Implementation Consortium (SCDIC). *J Immigr Minor Health*. 2020 Oct 9. doi: 10.1007/s10903-020-01102-6. Epub ahead of print. PMID: 33034793.

114. Linton EA, Goodin DA, Hankins JS, Kanter J, Preiss L, Simon J, Souffront K, Tanabe P, Gibson R, Hsu LL, King A, Richardson LD, Glassberg JA; **Sickle Cell Disease Implementation Consortium**. A Survey-Based Needs Assessment of Barriers to Optimal Sickle Cell Disease Care in the Emergency Department. *Ann Emerg Med*. 2020 Sep;76(3S):S64-S72. doi: 10.1016/j.annemergmed.2020.08.013. PMID: 32928465; PMCID: PMC7511000.
115. Hankins JS, Shah N, DiMartino L, Brambilla D, Fernandez ME, Gibson RW, Gordeuk VR, Lottenberg R, Kutlar A, Melvin C, Simon J, Wun T, Treadwell M, Calhoun C, Baumann A, Potter MB, Klesges L, Bosworth H; **Sickle Cell Disease Implementation Consortium**. Integration of Mobile Health Into Sickle Cell Disease Care to Increase Hydroxyurea Utilization: Protocol for an Efficacy and Implementation Study. *JMIR Res Protoc*. 2020 Jul 14;9(7):e16319. doi: 10.2196/16319. PMID: 32442144; PMCID: PMC7388044.

Pubmed:

<http://www.ncbi.nlm.nih.gov/sites/myncbi/matthew.smeltzer.1/bibliography/50372746/public/?sort=date&direction=descending>

ORCID:

0000-0003-1366-9267 <https://orcid.org/0000-0003-1366-9267>

**RECENT ABSTRACTS**

Smeltzer M, Faris N, Lee YS, Fehnel C, Akinbobola O, Jones C, Meadows-Taylor M, Saulsberry A, Dox H, Eubanks R, Valaulikar G, Talton D, Wolf B, Wiggins H, Sievers E, Levy P, Robbins E, Ray M, Osarogiagbon RU. Improving Overall Survival in Non-Small Cell Lung Cancer by Reducing R-Uncertain Resections With a Lymph Node Specimen Collection Kit. Abstract 1409. MA09.08. 2020 World Conference on Lung Cancer, Worldwide Virtual Event, January 28 - 31, 2021.

Smeltzer M. Tennessee Sickle Cell Disease Surveillance Program. Invited Presentation Tennessee Public Health Association Annual Meeting. September 10, 2020.

Smeltzer M, Ray M, Faris N, Meadows M, Fehnel C, Akinbobola O, Jackson B, Foust C, McHugh L, Signore R, Robbins E, Osarogiagbon R. Outcomes from a multidisciplinary thoracic oncology conference (MTOC) versus serial care (SC) in a community healthcare system. *J Clin Oncol* 38, 2020 (suppl 29; abstr 55). DOI: 10.1200/JCO.2020.38.29_suppl.55

Smeltzer M, Lee YS, Faris N, Fehnel C, Houston-Harris C, Meadows-Taylor M, Ray M, Mahul A, Fullenwider J, Okun S, Spencer D, Sales E, Osarogiagbon R. Improving Quality of Pathology Reports for Resected Non-Small Cell Lung Cancer (NSCLC) in the Mid-South US. OFP01.04. 2020 North America Conference on Lung Cancer, Worldwide Virtual Event October 16-17, 2020.

Smeltzer M, Boehmer L, Kramar A, Asfeldt T, Faris N, Amorosi C, Ray M, Nolan V, Oyer R, Lathan C, Osarogiagbon R. An Optimal Care Coordination Model (OCCM) for Medicaid patients with lung cancer: Results from the beta model testing phase of a multisite initiative in the United States. 2020 ASCO Quality Care Symposium Journal of Clinical Oncology 2020 38:29_suppl, 105-105

Smeltzer M, Boehmer L, Kramar A, Asfeldt T, Faris N, Ray M, Lathan C, Osarogiagbon R. An optimal care coordination model for Medicaid patients with lung cancer: Lessons learned from the beta testing phase of a multisite initiative in the United States. Abstract e14010. American Society of Clinical Oncology 2020 Virtual Scientific Program, Chicago, IL, May 29 to May 31, 2020. *Journal of Clinical Oncology* 38, no. 15_suppl.

Smeltzer M, Ray M, Faris N, Meadows M, Fehnel C, Akinbobola C, Jackson B, Foust C, McHugh L, Signore R, Robbins E, Osarogiagbon R. Outcomes from a multidisciplinary thoracic oncology conference (MTOC) versus serial care (SC) in a community healthcare system. 2020 ASCO Quality Care Symposium Journal of Clinical Oncology 2020 38:29_suppl, 55-55

Smeltzer M, Wynes M, Lantuejoul S, Soo RA, Dalurzo L, Felip E, Hollenbeck G, Howell K, Kerr K, Kim E, Mathias C, Postmus P, Powell C, Ramalingam S, Richeimer K, Taylor M, Tsuboi M, Varella-Garcia M, Wistuba I, Wood K, Scagliotti G, Hirsch F. Comparing Regional Results from the IASLC Global Survey on Molecular Testing in Lung Cancer. Oral Abstract Session Oct 11, 2019: Room 1, 14:00 - 15:4.

Smeltzer M, Wynes M, Taylor M, Richeimer K, Wood K, Howell K, Dalurzo M, Felip E, Kerr K, Kim E, Lantuejoul S, Mathias C, Postmus P, Powell C, Ramalingam S, Soo R, Tsuboi M, Wistuba I, Varella-Garcia M, Scagliotti G, Hirsch FR. The International Association for the Study of Lung Cancer (IASLC) Global Survey on Molecular Testing in Lung Cancer. MA21. Abstract 1198. 20th World Conference on Lung Cancer 2019.

Smeltzer M, Asfeldt T, Faris N, Kramar A, Amorosi C, Nolan V, Ray M, Dawkins M, Nalan MC, Stevens W, Lucas L, Oyer R, Lathan C, Osarogiagbon R. Testing an Optimal Care Coordination Model (OCCM) for Lung Cancer in a Multi-Site Study. MA19. Abstract 2659. 20th World Conference on Lung Cancer 2019. (Accepted)

Smeltzer MP, Stevens W, Faris NR, Kethireddy J, Meadows MB, Ray MA, Epperson A, Adams K, Fulford A, Wagh A, Machin J, Tonkin K, Optican R, Wright J, Robbins ET, Osarogiagbon RU. Lung cancer diagnosed by an incidental lung nodule program or lung cancer screening. Abstract 8546. ASCO Annual Meeting 2019; Chicago, IL.

Osarogiagbon RU, Faris NR, **Smeltzer M**, Ray M, Ward KD, Rugless F, Jackson BM, Meadows MB*, Berryman C, Fehnel C, Houston-Harris C. 2019. Prospective comparative effectiveness trial of multidisciplinary lung cancer (LC) care. *Journal of Clinical Oncology*; 37(15) 6549-6549.

Taylor M*, **Smeltzer M**, Faris N, Ray M, Fehnel C, Houston-Harris C, Akinbobola O*, Ojeabulu P, Osarogiagbon R. 2019 Racial Disparities in Long-Term Survival After Surgical Resection in the US. *Journal of Thoracic Oncology*;14(10) S602-S602.

Ray M, Faris NR, Derrick A, **Smeltzer M**, Osarogiagbon RU. 2019. The relative impact of patient and institutional rurality on lung cancer disparities. *Journal of Clinical Oncology*; 37(15) e20052-e20052.

M. Smeltzer, N. Faris, J. Kethireddy, M. Meadows, M. Nalan, M. Ray, A. Epperson, D. Richards, K. Adams, A. Fulford, A. Wagh, J. Machin, K. Tonkin, R. Optican, J. Wright, E. Robbins, R. Osarogiagbon. Comparing Lung Cancer Diagnosed by Low Dose CT (LDCT), Incidental Lung Nodule Program (ILNP), and non-program based detection. 19th World Conference on Lung Cancer 2018. P1.11-11

A. Marbaugh, T. Asfeldt, R. Oyer, C. Lathan, **M. Smeltzer**, V. Nolan, M. Ray, N. Faris, M. Nalan, W. Stevens, A. Kramar, L. Lucas, R. Osarogiagbon. Creating an optimal care coordination model to improve multidisciplinary care for lung cancer patients on Medicaid. 19th World Conference on Lung Cancer 2018. P1.15-21

M. Smeltzer, N. Faris, M. Ray, C. Fehnel, O. Akinbobola, C. Houston-Harris, P. Ojeabulu, Y. Lee, E. Owen, R. Eubanks, H. Dox, D. Talton, H. Wiggins, B. Wolf, P. Levy, E. Robbins, R. Osarogiagbon. A population-based validation study of the proposed 'R-Factor' classification in a lung cancer endemic region of the US. 19th World Conference on Lung Cancer 2018. P1.16-46

M. Ray, **M. Smeltzer**, N. Faris, Y. Lee, C. Fehnel, C. Houston-Harris, O. Akinbobola, P. Ojeabulu, E. Owen, R. Eubanks, H. Dox, D. Talton, G. Valaulikar, H. Wiggins, B. Wolf, P. Levy, E. Robbins, R. Osarogiagbon. Pattern and Survival impact of neoadjuvant treatment of non-small cell lung cancer (NSCLC) in a prospective lung resection cohort. 19th World Conference on Lung Cancer 2018. P1.17-11

Y. Lee*, **M. Smeltzer**, M. Ray, N. Faris, C. Fehnel, C. Houston-Harris, O. Akinbobola, P. Ojeabulu, E. Owen, R. Eubanks, H. Dox, D. Talton, H. Wiggins, B. Wolf, P. Levy, E. Robbins, R. Osarogiagbon. Survival implications and factors associated with the anatomic level of incomplete non-small cell lung cancer (NSCLC) resection. 19th World Conference on Lung Cancer 2018. P2.16-32

M. Ray, **M. Smeltzer**, N. Faris, Y. Lee, C. Fehnel, C. Houston-Harris, O. Akinbobola, P. Ojeabulu, E. Owen, R. Eubanks, H. Dox, D. Talton, G. Valaulikar, H. Wiggins, B. Wolf, P. Levy, E. Robbins, R. Osarogiagbon. Characteristics of preoperative N staging in patients with optimal pathologic N staging of non-small cell lung cancer (NSCLC). P2.16-38

N. Faris, Y. Lee, **M. Smeltzer**, M. Ray, C. Fehnel, C. Houston-Harris, O. Akinbobola, P. Ojeabulu, E. Owen, R. Eubanks, H. Dox, D. Talton, G. Valaulikar, H. Wiggins, B. Wolf, P. Levy, E. Robbins, R. Osarogiagbon. Characteristics and survival of resected stage IV non-small cell lung cancer (NSCLC) in the mid-south quality of surgical resection cohort. 19th World Conference on Lung Cancer 2018. MA25.05

Osarogiagbon RU, **Smeltzer MP**, Faris NR, Ray MA, Fehnel C, Houston-Harris C, Ojeabulu P, Akinbobola O, Wiggins HL, Talton D, Owen Ed, Deese L, Eubanks R, Wolf BA, Robbins ET. Pragmatic Study of a Lymph Node (LN) Collection Kit for Non-Small Cell Lung Cancer (NSCLC) Resection. Abstract #224733. ASCO; June 1-5, 2018; Chicago, IL.

Smeltzer MP, Ray MA, Faris NR, Meadows MB, Fehnel C, Houston-Harris C, Ojeabulu P, Akinbobola O, Lee YS, Wiggins HL, Talton D, Owen E, Deese L, Eubanks R, Wolf BA, Robbins ET, Osarogiagbon RU. Survival in the Population-based Mid-South Quality of Surgical Resection (MSQSR) Cohort. Abstract #229193. ASCO; June 1-5, 2018; Chicago, IL.

Ray MA, **Smeltzer MP**, Faris NR, Fehnel C, Houston-Harris C, Ojeabulu P, Akinbobola O, Wiggins HL, Talton D, Owen E, Deese L, Eubanks R, Wolf BA, Robbins ET, Osarogiagbon RU. Implementing improved pathologic nodal (pN) staging during non-small cell lung cancer (NSCLC) resection: a population-based study. Abstract #225079. ASCO; June 1-5, 2018; Chicago, IL.

Ward KD, Chen W, **Smeltzer MP**, Meadows MB, Faris NR, Berryman C, Jackson BM, Rugless F, Ray MA, Osarogiagbon RU. Patient-Reported Satisfaction with Multidisciplinary (MD) v Serial Care (SC) for Lung Cancer. Abstract #223713 ASCO; June 1-5, 2018; Chicago, IL.

Smeltzer MP, Lee YS, Faris NR, Ray MA, Fehnel C, Houston-Harris C, Ojeabulu P, Akinbobola O, Deese L, Owen E, Wolf B, Wiggins HL, Mutrie V, Sachdev V, Levy P, Signore RS, Robbins ET, Osarogiagbon RU. Thoroughness of staging and the outcomes of surgical resection in potentially curable non-small cell lung cancer (NSCLC). 18th World Conference on Lung Cancer 2017. OA 15 - Diagnostic Radiology, Staging and Screening for Lung Cancer II. Oct 18, 2017.

Ward KD, **Smeltzer MP**, Rugless FE, Faris NR, Ray MA, Jackson B, Foust C, Patel A, Meadows M, Boateng N, Roark K, Crossley F, Oliver G, McHugh L, Hastings W, Osborne O, Osborne J, III T, III M, Signore RS, Fox R, Robbins ET, Osarogiagbon RU. Prospective Comparative Evaluation of Patient and Caregiver Perspectives on a Multidisciplinary Model of Lung Cancer Care . 18th World Conference on Lung Cancer 2017, MA 04 - Advocacy: Listen to the Patients. Oct 16, 2017.

Smeltzer MP, Rugless FE, Lee HK, Ward KD, Faris N, Ray MA, Meadows M, Jiang B, Jackson B, Foust C, Patel A, Boateng N, Kedia S, Roark K, Houston-Harris C, Fehnel C, Signore RS, Fox R, Robbins ET, Li J, Osarogiagbon RU. Prospective Evaluation of Multidisciplinary Lung Cancer Care: Timeliness, Thoroughness, and Patient/Caregiver Perspectives. IASLC 2017 Chicago Multidisciplinary Symposium in Thoracic Oncology Oral 4B.03. September 15, 2017.

Smeltzer MP, Meadows MB, Faris NR, Stewart FE, Ray M, Lee YS, Boateng N, Foust C, Jackson B, Patel A, Fehnel C, Houston-Harris C, Signore RS, Robbins ET, Osarogiagbon RU. Increased Use of PET-CT, Invasive Staging, and Surgical Resection with a Multidisciplinary Lung Cancer Care Model: Effectiveness Endpoints from an Implementation Study. Annals of Epidemiology, 2017 ACE Meeting Abstract PS12.

Smeltzer M, Faris N, Stewart F, Ray M, Boateng N, Meadows M, Foust C, Jackson B, Patel A, Fehnel C, Houston-Harris S, Signore R, Robbins E, Osarogiagbon R. Staging in multidisciplinary (MDC) v serial care (SC) lung cancer (LCa) patients (Pts). J Clin Oncol 35, 2017 (suppl; abstr e20079)

Ward K, Boateng N, Stewart F, **Smeltzer M**, Jackson B, Foust C, Faris N, Ray M, Osarogiagbon R. Satisfaction among lung cancer (LCa) patients (pts) in multidisciplinary (MDC) vs. serial care (SC) settings. J Clin Oncol 35, 2017 (suppl; abstr e18254)

Ray M, Faris N, Stewart F, **Smeltzer M**, Boateng N, Meadows M, Foust C, Jackson B, Patel A, Fehnel C, Houston-Harris C, Signore R, Robbins E, Osarogiagbon R. Treatment of lung cancer patients in multidisciplinary (MDC) and serial care (SC) clinics. J Clin Oncol 35, 2017 (suppl; abstr 8522).

Smeltzer M, Klesges L, Lee YS, Faris N, Fehnel C, Houston-Harris C, Ray M, Robbins E, Osarogiagbon R. Reach and Adoption of a Surgical Intervention To Improve Pathologic Nodal Staging Across Healthcare Systems within the US. 2016 Mid-South IASLC Chicago Multidisciplinary Symposium in Thoracic Oncology (Abstract 111).

Smeltzer M, Lee YS, Robbins E, Faris N, Mutrie C, Ray M, Signore S, Fehnel C, Houston-Harris C, Meadows M, Osarogiagbon R. Predictors of Post-Operative Mortality in Non-Small Cell Lung Cancer (NSCLC) in a High Mortality Region of the US. 17th World Conference on Lung Cancer, December 4-8, 2016 (Abstract 4447).

Smeltzer M, Faris N, Fehnel C, Houston-Harris C, Ray M, Lee YS, Meadows M, Robbins E, Signore S, Mutrie C, Osarogiagbon R. Validation of the IASLC 8th Edition (8E) TNM Classification for Non-Small Cell Lung Cancer by the Quality of Surgical Resection in a US Cohort. 17th World Conference on Lung Cancer, December 4-8, 2016 (Abstract 6237).

Smeltzer M, Faris N, Fehnel C, Houston-Harris C, Ray M, Lee YS, Meadows M, Signore S, Mutrie C, Robbins E, Osarogiagbon R. The Impact of IASLC 8th Edition Updates for T-Classification for Lung Cancer in a US Population-Based Surgical Resection Cohort. 17th World Conference on Lung Cancer, December 4-8, 2016 (Abstract 6241).

Smeltzer M, Klesges L, Lee YS, Faris N, Ray M, Fehnel C, Houston-Harris C, Signore S, Robbins E, Osarogiagbon R. The Reach and Adoption of a Surgical Intervention for Lung Cancer Across Healthcare Systems within the US Mid-South Region. 9th Annual Conference on the Science of Dissemination and Implementation (December 2016).

Smeltzer M, Stewart F, Faris N, Foust C, Jackson B, Roark K, McHugh L, Signore R, Oliver G, Robbins E, Klesges L, Osarogiagbon R; The reach of a community-based multidisciplinary (MD) thoracic oncology program (P). J Clin Oncol 34, 2016 (suppl; abstr e18045)

Osarogiagbon R, Lin CC, **Smeltzer M**, Jemal A. Overall survival (OS) implications of institutional disparities in non-small cell lung cancer (NSCLC) pathologic nodal (pN) staging practice in the National cancer data base (NCDB). J Clin Oncol 34, 2016 (suppl; abstr 6554)

Jemal A, Lin CC, **Smeltzer M**, Osarogiagbon R. Non-examination of lymph nodes (LN) and overall survival (OS) in non-small cell lung cancer (NSCLC) patients. J Clin Oncol 34, 2016 (suppl; abstr 8547)

Lin CC, **Smeltzer M**, Jemal A, Osarogiagbon R. Risk-adjusted margin positivity (RAMP) rate as a surgical quality metric for non-small-cell lung cancer (NSCLC). J Clin Oncol 34, 2016 (suppl; abstr 8551)

Stewart F, **Smeltzer M**, Faris N, Foust C, Jackson B, Roark K, McHugh L, Signore S, Oliver G, Robbins E, Klesges L, Osarogiagbon R. Variance in Multidisciplinary (MultiD) recommendations in a conference only vs co-located clinic model. J Clin Oncol 34, 2016 (suppl; abstr e18039)

Faris N, Lu F, **Smeltzer M**, Fehnel C, Chakraborty N, Houston-Harris C, Signore R, Robbins E, Osarogiagbon R. Use and performance of mediastinoscopy before surgery for non-small cell lung cancer (NSCLC) in the Mid-South region of the United States (US). J Clin Oncol 34, 2016 (suppl; abstr 8543)

Smeltzer MP, Lin CC, Yu X, Jemal A, and Osarogiagbon RU. Survival Impact of Post-Operative Therapy Modalities After Incomplete and Complete Surgical Resection for Non-Small Cell Lung Cancer in the US. 16th World Conference on Lung Cancer, September 6-9, 2015 (ORAL 20.07).

Smeltzer, Rugless, Faris, Yu, Eke, Relyea, Fehnel, Chakraborty, Houston-Harris, Lu, Spencer, Berry, Sales, Finch-Cruz, and Osarogiagbon. Trends in Accuracy and Comprehensiveness of Pathology Reports of Resected Non-small Cell Lung Cancer (NSCLC) in a High Mortality Area of the US. 16th World Conference on Lung Cancer, September 6-9, 2015 (P1.12-001).

X. Yu, N. Faris, R. Eke, **M.P. Smeltzer**, G. Relyea, F.E. Rugless, C. Fehnel, N. Chakraborty, C. Houston-Harris, F. Lu, E.T. Robbins, R.S. Signore, L. McHugh, B. Wolf, C. Mutrie, L. Deese, P. Levy, E. Crocker, L. Wiggins, R.U. Osarogiagbon. Impact of Attainment of the American College of Surgeons Commission on Cancer Quality Measure on Patient Survival After Lung Cancer Resection. 16th World Conference on Lung Cancer, September 6-9, 2015 (MINI06.04).

C.C. Lin, **M.P. Smeltzer**, X. Yu, R.U. Osarogiagbon, A. Jemal. Risk-Adjusted Margin Positivity (RAMP) Rate as a Surgical Quality Metric for Non-Small-Cell Lung Cancer in the US National Cancer Data Base (NCDB). 16th World Conference on Lung Cancer, September 6-9, 2015 (MINI20.02).

N. Faris, **M.P. Smeltzer**, C. Adair, A. Berry, X. Yu, L. McHugh, R.U. Osarogiagbon - The Survival Impact of Missed Lymph Node Metastasis in Surgically Resected Non-Small Cell Lung Cancer (NSCLC). 16th World Conference on Lung Cancer, September 6-9, 2015 (MINI20.03).

X. Yu, E.T. Robbins, N. Faris, R.S. Signore, L. McHugh, R. Eke, **M.P. Smeltzer**, G. Relyea, C. Fehnel, N. Chakraborty, C. Houston-Harris, F. Lu, B. Wolf, C. Mutrie, L. Deese, E. Crocker, L. Wiggins, P. Levy, R.U. Osarogiagbon Evolution in the Surgical Care of Non-Small Cell Lung Cancer (NSCLC) Patients in the Mid-South Quality of Surgical Resection (MS-QSR) Cohort. 16th World Conference on Lung Cancer, September 6-9, 2015 (ORAL30.01).

N. Faris, X. Yu, R. Eke, **M.P. Smeltzer**, G. Relyea, F.E. Rugless, C. Fehnel, N. Chakraborty, C. Houston-Harris, F. Lu, E.T. Robbins, R.S. Signore, L. McHugh, B. Wolf, C. Mutrie, L. Deese, P. Levy, E. Crocker, L. Wiggins, R.U. Osarogiagbon. Impact of Attainment of National Comprehensive Cancer Network (NCCN) Quality Parameters on Patient Survival after Resection of Lung Cancer. 16th World Conference on Lung Cancer, September 6-9, 2015 (ORAL34.02).

R.U. Osarogiagbon, G. Relyea, N. Faris, X. Yu, R. Eke, **M.P. Smeltzer**, F.E. Rugless, C. Fehnel, N. Chakraborty, C. Houston-Harris, F. Lu, R.S. Signore, L. McHugh, L. Deese, P. Levy, E. Crocker, L. Wiggins, C. Mutrie, B. Wolf, E.T. Robbins. Impact of Surgeons' Attainment of Quality Resection Parameters on Non-Small-Cell Lung Cancer (NSCLC) Patients' Survival. 16th World Conference on Lung Cancer, September 6-9, 2015 (ORAL34.06).

R.U. Osarogiagbon, C.C. Lin, **M.P. Smeltzer**, A. Jemal- Prevalence, Prognostic Implications and Survival Modulators of Incompletely Resected Non-Small Cell Lung Cancer (NSCLC) in the US. 16th World Conference on Lung Cancer, September 6-9, 2015. (ORAL34.07)

Smeltzer MP, Nolan V, Nottage K, Wang W, Gurney J, and Hankins J. Prevalence of sickle cell trait and sickle cell disease among African American live births in Shelby Co., TN. Presentation at the American Public Health Association Annual Meeting. November 2013.

Smeltzer MP, Aygun B, Nolan V, Davis B, Wang W, and Hankins J. Greater Distance from a Sickle Cell Center Does Not Compromise Routine Healthcare Management. Presented at the Global Sickle Cell Disease Network Conference, March 2012.

COMMITTEE AND ADMINISTRATIVE SERVICE

Communications Committee- International Association for the Study of Lung Cancer (IASLC), 2019-
Publications Committee- International Association for the Study of Lung Cancer (IASLC), 2017-2019
Steering Committee- SCCRIP: Lifetime Cohort Study for Sickle Cell Disease (St. Jude Children's Res. Hosp.)
National Needs Assessment Committee- NHLBI Sickle Cell Disease Implementation Consortium (SCDIC)
American College of Epidemiology, Associate Members Leadership Committee, 2014-2016
Admissions Committee, Master in Public Health, University of Memphis. 2015-2019
Admissions Committee, PhD in Epidemiology, University of Memphis. 2018-2021
Admissions Committee Chair, PhD in Epidemiology, University of Memphis. 2021-
Comprehensive Examination Committee, PhD in Epidemiology, University of Memphis.
Judge for 2017 Graduate Research Symposium, University of Memphis

MEMBERSHIPS

American College of Epidemiology
 American Statistical Association
 American Society of Clinical Oncology
 International Association for the Study of Lung Cancer
 SAS Users Group, Memphis

REVIEWER

Editorial Board Member- Translational Lung Cancer Research, 2021-
 Review Team Member- Journal of Thoracic Oncology, 2018-
 Ad hoc reviewer- Pediatric Blood and Cancer, 2013-
 Ad hoc reviewer- American Journal of Health Behavior, 2013-
 National Undergraduate Research Conference 2017

RESEARCH SUPPORT

NU58DD000019-01-00 (Core Comp) (PI: Smeltzer (contact)/Hankins/Davis/Cooper) 09/30/2020 – 09/29/2023
 Tennessee Sickle Cell Disease Surveillance Program – Core Component
 Role: Contact Principal Investigator (MPI)
 Source: Centers for Disease Control and Prevention
 Total Amount: \$748,212

NU58DD000019-02-01 (Optional Comp.) (PI: Smeltzer (contact)/Hankins/Davis/Cooper) 09/30/2021 – 09/29/2022
 Tennessee Sickle Cell Disease Surveillance Program – Optional Component
 Role: Contact Principal Investigator (MPI)
 Source: Centers for Disease Control and Prevention
 Total Amount: \$225,000

NU58DD000019-02-01 (CARES Suppl.) (PI: Smeltzer (contact)/Hankins/Davis/Cooper) 09/30/2021 – 09/29/2022
 Tennessee Sickle Cell Disease Surveillance Program – CARES Act Supplement
 Role: Contact Principal Investigator (MPI)
 Source: Centers for Disease Control and Prevention
 Total Amount: \$130,088

Analysis of Global Survey on COVID-19 and Clinical Trials (PI: Smeltzer) 03/01/2021 – 02/28/2022
 International Assoc. for the Study of Lung Cancer
 Role: Principal Investigator

2-R01CA172253 (PI: Raymond Osarogiagbon, MBBS). 08/01/2018-7/31/2023
 Improving N1 lymph node examination in a high US lung cancer mortality region.

National Cancer Institute (NIH)
Role: Site Principal Investigator

Analysis of Global Survey on Molecular Testing in Lung Cancer (PI: Smeltzer) 05/01/2019 – 04/30/2020
International Assoc. for the Study of Lung Cancer
Role: Principal Investigator

U01HL133996-01 (PI: Jane Hankins, MD, M.S) 07/01/2016-06/30/2022
ReHASH: Re-aiming at Hydroxyurea Adherence for Sickle Cell with mHealth
National Heart Lung and Blood Institute (NIH)
Role: Site Principal Investigator

Centers for Disease Control and Prevention DD19-1906 09/15/2019 – 09/14/2020
(PI: Davis/Hankins/Smeltzer/Cooper)
Building Capacity for the Tennessee Sickle Cell Disease Surveillance Program
Role: Multiple Principal Investigator

Epidemiology, Biostatistics, and Data Coordinating Center (EBDCC) 07/01/2017 - 8/31/2019
Creating an Optimal Care Coordination Model for Lung Cancer Patients on Medicaid
Association of Community Cancer Centers
Total EBDCC budget: \$320,000
Role: Principal Investigator

R01CA172253 (PI: Raymond Osarogiagbon, MBBS). 04/01/2013-07/31/2018
Dissemination of a Corrective Intervention to Improve Lymph Node Examination in Resected Lung Cancer;
National Cancer Institute (NIH)
Role: Co-Investigator

R073223660 (PI: Robert Davis, MD). 11/01/2016-10/01/2021
ECOSYSTENN: Education and Clinical Outcomes in Youth with Sickle Cell in Tennessee
Memphis Research Consortium
Role: Site Principal Investigator

IH-1304-6147. (PI: Raymond Osarogiagbon, MBBS). 02/03/2014 – 08/02/2017
Building a multidisciplinary bridge across the quality chasm in thoracic oncology.
Patient Centered Outcomes Research Institute (PCORI)
Role: Co-Investigator

S3595 (PI: Matthew Smeltzer, PhD) 01/01/2016 - 01/01/2017
A quantitative evaluation to inform a future provider-level educational intervention to address suboptimal
hydroxyurea utilization for sickle cell disease in Shelby County, TN.
Memphis Research Consortium
Role: Principal Investigator

Epidemiology and Biostatistics Support for (PI: Matthew Smeltzer, PhD) 03/15/2015 - 08/31/2017
Baptist Lung Multidisciplinary (lung MD) Program
Total Project Costs: \$118,925
Role: Principal Investigator

R15 EB022345-01A1 (PI: Gary Bowlin, PhD) 04/17/2017 - 04/17/2019
Neutrophil Response to Tissue Templates in Vitro: Implant Implications

National Institutes of Health (NIH)
Total projected costs \$427,409
Role: Co-Investigator, 5% effort

R21 EB024131-01 (PI: Gary Bowlin) 04/24/2017 - 04/24/2019
Designing Drug-eluting Regeneration Templates to Down-regulate Neutrophil
Extracellular Traps
National Institutes of Health (NIH)
Role: Co-Investigator, 5% effort

R01HL098239-03 (PI: Russell Ware, MD, Ph.D., James Boyett, Ph.D.) 9/01/2010 – 08/31/2013
To serve as the Data Coordinating Center, SCATE (Multicenter International RCT of Hydroxyurea Use in
Pediatric Sickle Cell Disease).
National Heart Lung and Blood Institute (NIH)
Role: Biostatistician

R01DK088988-03 (PI: Claudia Hillenbrand, Ph.D., Jane Hankins, MD, M.S.) 08/01/2010 – 04/30/2014
To develop, implement, and validate in patients with hepatic iron overload an ultra short echo time MRI
technique - R2*-UTE .
National Heart Lung and Blood Institute (NIH)
Role: Biostatistician

HRSA 10-094 – 1 U1EMC19331-01-00 (PI: Jane Hankins, MD, M.S) 09/01/2010 - 08/31/2014
Sickle Cell Treatment Demonstration Program: To enhance the prevention and treatment of sickle cell
disease through coordination of service delivery, genetic counseling and testing, bundling of technical
services, training of health professionals, and continuity of care for individuals with sickle cell disease.
Role: Biostatistician